Patent licensing agreement

24. Sep 2018 | 1 min read

Moss 24.09.2018

Gentian Diagnostics AS announces today that one of its subsidiaries has entered into an agreement to license out a non-core portfolio of patents to an undisclosed third party. Gentian will receive a lump sum of USD 750,000 to provide a fully paid up global licence for the patents. The grant of this patent licence is not expected to have any impact on the Company's revenues going forward. The Company will recognize the revenues from this agreement in the 3rd quarter of 2018.

For further information, please contact:
Njaal Kind CFO, Gentian Diagnostics AS
E-mail: njaal.kind@gentian.no
Cell Phone: +47 919 06 525

 

MeldingsID: 459987
UtstederID: GENT-ME
Instrument: GENT-ME
Marked: Merkur Market
Kategori: INNSIDEINFORMASJON

You may also read


Feb 12, 2026 - Ole Sørlie

Gentian Diagnostics: Key information relating to the proposed cash dividend

Moss, 12 February 2026 The Board of Directors of Gentian Diagnostics ASA proposes a dividend of NOK 0.60 per..

Feb 11, 2026 - Ole Sørlie

Update on the development of the NT-proBNP assay

Gentian Diagnostics ASA announces an update on the development of its NT proBNP assay. Recent investigations..

Feb 11, 2026 - Ole Sørlie

Gentian Diagnostics: Fourth quarter 2025 report

Moss, 11 February 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic..